The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | A | Alimentary tract and metabolism | |
| 2 | A16 | Other alimentary tract and metabolism products | |
| 3 | A16A | Other alimentary tract and metabolism products | |
| 4 | A16AA | Amino acids and derivatives | |
| 5 | A16AA06 | Betaine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 6 g |
| Active Ingredient | Description | |
|---|---|---|
| Betaine |
Betaine anhydrous was shown to lower plasma homocysteine levels in the three types of homocystinuria, i.e. CBS deficiency; MTHFR deficiency and cbl defect. The extent of this effect was dependent on the absolute degree of hyperhomocysteinemia, being higher in severe hyperhomocysteinemia. Betaine anhydrous acts as a methyl group donor in the remethylation of homocysteine to methionine in patients with homocystinuria. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| AMVERSIO Oral powder | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CYSTADANE Oral powder | European Medicines Agency (EU) | MPI, EU: SmPC | |
| CYSTADANE Powder for oral solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
